Thrivent Financial for Lutherans Sells 3,603 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Thrivent Financial for Lutherans lowered its position in shares of Inari Medical, Inc. (NASDAQ:NARI) by 8.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,351 shares of the company’s stock after selling 3,603 shares during the quarter. Thrivent Financial for Lutherans owned 0.07% of Inari Medical worth $1,623,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Lighthouse Investment Partners LLC purchased a new stake in shares of Inari Medical during the second quarter valued at approximately $2,145,000. Aigen Investment Management LP purchased a new stake in shares of Inari Medical during the 3rd quarter valued at $428,000. Integral Health Asset Management LLC increased its position in shares of Inari Medical by 100.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock valued at $19,260,000 after purchasing an additional 200,000 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Inari Medical by 1,219.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 394,901 shares of the company’s stock worth $19,014,000 after purchasing an additional 364,983 shares during the period. Finally, Financial Enhancement Group LLC purchased a new position in shares of Inari Medical in the 3rd quarter worth about $1,155,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Insider Activity at Inari Medical

In other news, CFO Mitch C. Hill sold 3,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now directly owns 179,600 shares in the company, valued at $8,105,348. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William Hoffman sold 60,000 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the completion of the transaction, the director now directly owns 501,233 shares in the company, valued at approximately $25,643,080.28. The trade was a 10.69 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 186,000 shares of company stock worth $8,990,990. 10.60% of the stock is owned by company insiders.

Inari Medical Price Performance

NASDAQ:NARI opened at $51.92 on Friday. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $67.13. The stock’s fifty day moving average price is $46.14 and its two-hundred day moving average price is $47.48. The company has a market cap of $3.04 billion, a P/E ratio of -38.46 and a beta of 0.96.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Canaccord Genuity Group raised their price objective on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Piper Sandler raised their price target on shares of Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 29th. Stifel Nicolaus started coverage on shares of Inari Medical in a report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price target on the stock. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Finally, Leerink Partners assumed coverage on Inari Medical in a research report on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 target price for the company. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Inari Medical presently has a consensus rating of “Hold” and an average target price of $58.89.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.